SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

June 26, 2013 08:30 ET

Atossa Genetics to Present at Two Upcoming Investor Conferences

SEATTLE, WA--(Marketwired - Jun 26, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced that Kyle Guse, CFO and General Counsel, will be presenting at two upcoming investor conferences: the JMP Securities Healthcare Conference in New York City and the Life Science Innovation Northwest 2013 Conference in Seattle.

The JMP Securities Healthcare Conference presentation will take place on Tuesday, July 9, 2013, at 2:00 pm Eastern Time at the St. Regis Hotel. The Life Science Innovation Northwest 2013 Conference presentation will take place on Wednesday, July 10, 2013, at 10:45 am Pacific Time at the Washington State Convention Center. 

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests, including its ForeCYTE Breast Health Test which can detect precursors to breast cancer up to eight years before mammography.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa and its medical devices, please visit www.atossagenetics.com. For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.

Contact Information

  • Contact:

    Atossa Genetics, Inc.
    Kyle Guse
    Chief Financial Officer and General Counsel
    800-351-3902
    Email Contact

    Matthew D. Haines (Investors)
    Managing Director
    MBS Value Partners
    212-710-9686
    Email Contact